IL129922A0 - Tissue specific expression of retinoblastoma protein - Google Patents
Tissue specific expression of retinoblastoma proteinInfo
- Publication number
- IL129922A0 IL129922A0 IL12992297A IL12992297A IL129922A0 IL 129922 A0 IL129922 A0 IL 129922A0 IL 12992297 A IL12992297 A IL 12992297A IL 12992297 A IL12992297 A IL 12992297A IL 129922 A0 IL129922 A0 IL 129922A0
- Authority
- IL
- Israel
- Prior art keywords
- specific expression
- retinoblastoma protein
- tissue specific
- retinoblastoma
- protein
- Prior art date
Links
- 108050002653 Retinoblastoma protein Proteins 0.000 title abstract 2
- 102000001388 E2F Transcription Factors Human genes 0.000 abstract 1
- 108010093502 E2F Transcription Factors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4736—Retinoblastoma protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75151796A | 1996-11-15 | 1996-11-15 | |
US08/801,092 US6074850A (en) | 1996-11-15 | 1997-02-14 | Retinoblastoma fusion polypeptides |
PCT/US1997/021821 WO1998021228A1 (en) | 1996-11-15 | 1997-11-13 | Tissue specific expression of retinoblastoma protein |
Publications (1)
Publication Number | Publication Date |
---|---|
IL129922A0 true IL129922A0 (en) | 2000-02-29 |
Family
ID=27115430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12992297A IL129922A0 (en) | 1996-11-15 | 1997-11-13 | Tissue specific expression of retinoblastoma protein |
Country Status (16)
Country | Link |
---|---|
US (2) | US6902731B1 (xx) |
EP (1) | EP0948520B1 (xx) |
JP (1) | JP4109721B2 (xx) |
KR (1) | KR100336551B1 (xx) |
CN (1) | CN100338219C (xx) |
AT (1) | ATE286908T1 (xx) |
AU (1) | AU723660B2 (xx) |
BR (1) | BR9712767B1 (xx) |
CA (1) | CA2271478C (xx) |
DE (1) | DE69732246T2 (xx) |
ES (1) | ES2234040T3 (xx) |
HK (1) | HK1019751A1 (xx) |
HU (1) | HU226662B1 (xx) |
IL (1) | IL129922A0 (xx) |
NZ (1) | NZ335738A (xx) |
WO (1) | WO1998021228A1 (xx) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1054969A2 (en) * | 1998-02-12 | 2000-11-29 | Curagen Corporation | Retinoblastoma protein complexes and retinoblastoma interacting proteins |
WO2000022124A2 (en) * | 1998-10-15 | 2000-04-20 | Canji, Inc. | Methods and compositions to induce antitumor response |
AU758354B2 (en) * | 1998-10-15 | 2003-03-20 | Canji, Inc. | Selectively replicating viral vectors |
US7691370B2 (en) * | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
US6649158B1 (en) | 1998-10-15 | 2003-11-18 | Canji, Inc. | Methods and compositions to induce antitumor response |
WO2002050101A1 (en) * | 2000-12-19 | 2002-06-27 | The Council Of The Queensland Institute Of Medical Research | Retinoblastoma-binding protein |
US6866994B2 (en) * | 2001-05-30 | 2005-03-15 | Neomatrix, Llc | Noninvasive intraductal fluid diagnostic screen |
CN103463646A (zh) * | 2013-09-19 | 2013-12-25 | 浙江大学 | E2f1蛋白在制备诊断和治疗骨肉瘤药物中的应用 |
US9895446B2 (en) | 2015-07-14 | 2018-02-20 | Professional Compounding Centers Of America | Poloxamer-based intralesional injections for the delivery of chemotherapeutic agents |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
AU660629B2 (en) | 1990-10-01 | 1995-07-06 | University Of Connecticut, The | Targeting viruses and cells for selective internalization by cells |
WO1993014188A1 (en) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Targeted virus |
ES2221920T3 (es) | 1992-04-03 | 2005-01-16 | The Regents Of The University Of California | Sistema de liberacion de polinucleotidos de autoensamblaje que comprende un peptido cationico anfipatico. |
AU3940293A (en) | 1992-04-03 | 1993-11-08 | Alexander T. YOUNG | Gene therapy using targeted viral vectors |
US5656609A (en) | 1992-09-24 | 1997-08-12 | University Of Connecticut | Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine |
WO1994006923A1 (en) | 1992-09-24 | 1994-03-31 | The University Of Connecticut | Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells |
ZA947065B (en) * | 1993-09-13 | 1995-05-03 | Univ California | Therapeutic use of the retinoblastoma susceptibility gene product |
US5473056A (en) * | 1993-10-13 | 1995-12-05 | Merck & Co., Inc. | E2F-2, a novel mammalian transcription factor |
-
1997
- 1997-11-13 IL IL12992297A patent/IL129922A0/xx active IP Right Grant
- 1997-11-13 AT AT97952238T patent/ATE286908T1/de not_active IP Right Cessation
- 1997-11-13 CN CNB971813175A patent/CN100338219C/zh not_active Expired - Fee Related
- 1997-11-13 CA CA002271478A patent/CA2271478C/en not_active Expired - Fee Related
- 1997-11-13 HU HU9903864A patent/HU226662B1/hu not_active IP Right Cessation
- 1997-11-13 ES ES97952238T patent/ES2234040T3/es not_active Expired - Lifetime
- 1997-11-13 DE DE69732246T patent/DE69732246T2/de not_active Expired - Lifetime
- 1997-11-13 BR BRPI9712767-1A patent/BR9712767B1/pt not_active IP Right Cessation
- 1997-11-13 NZ NZ335738A patent/NZ335738A/en not_active IP Right Cessation
- 1997-11-13 KR KR1019997004327A patent/KR100336551B1/ko not_active IP Right Cessation
- 1997-11-13 WO PCT/US1997/021821 patent/WO1998021228A1/en active IP Right Grant
- 1997-11-13 JP JP52295898A patent/JP4109721B2/ja not_active Expired - Fee Related
- 1997-11-13 AU AU55899/98A patent/AU723660B2/en not_active Ceased
- 1997-11-13 EP EP97952238A patent/EP0948520B1/en not_active Expired - Lifetime
-
1999
- 1999-05-19 US US09/315,116 patent/US6902731B1/en not_active Expired - Fee Related
- 1999-05-19 US US09/315,113 patent/US6379927B1/en not_active Expired - Lifetime
- 1999-10-15 HK HK99104577A patent/HK1019751A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HU226662B1 (en) | 2009-06-29 |
CN100338219C (zh) | 2007-09-19 |
EP0948520B1 (en) | 2005-01-12 |
AU5589998A (en) | 1998-06-03 |
HK1019751A1 (en) | 2000-02-25 |
ES2234040T3 (es) | 2005-06-16 |
JP2001503638A (ja) | 2001-03-21 |
KR100336551B1 (ko) | 2002-05-11 |
DE69732246T2 (de) | 2005-12-08 |
ATE286908T1 (de) | 2005-01-15 |
CA2271478C (en) | 2003-02-04 |
AU723660B2 (en) | 2000-08-31 |
HUP9903864A3 (en) | 2001-09-28 |
DE69732246D1 (de) | 2005-02-17 |
CA2271478A1 (en) | 1998-05-22 |
EP0948520A1 (en) | 1999-10-13 |
WO1998021228A1 (en) | 1998-05-22 |
JP4109721B2 (ja) | 2008-07-02 |
KR20000053323A (ko) | 2000-08-25 |
US6902731B1 (en) | 2005-06-07 |
CN1244870A (zh) | 2000-02-16 |
EP0948520A4 (en) | 2003-03-12 |
BR9712767B1 (pt) | 2010-11-30 |
NZ335738A (en) | 2001-02-23 |
US6379927B1 (en) | 2002-04-30 |
HUP9903864A2 (hu) | 2001-04-28 |
BR9712767A (pt) | 1999-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU5671594A (en) | Human tissue factor related dna segments, polypeptides and antibodies | |
NZ506783A (en) | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities | |
AU6549898A (en) | Method for the broad based treatment of infections, especially infections of organs such as the skin and vagina | |
AU1049788A (en) | Methods and peptides for the treatment of non-ige-mediated diseases | |
NO986089D0 (no) | Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o | |
NZ332720A (en) | Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia | |
AU9312198A (en) | Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer | |
IL110464A0 (en) | Novel proteins for the diagnosis, imaging, and therapy of human cancer | |
HU9401260D0 (en) | Fema gene of staphylococcus epidermis, fema protein, and vectors and microorganisms comprising the fema gene | |
HK1019751A1 (en) | Tissue specific expression of retinoblastoma protein. | |
EP0209543A4 (en) | FRAGMENTS OF HUMAN APOLIPOPROTEINS PEPTIDES, TYPE-SPECIFIC ANTIBODIES AND METHODS OF USE. | |
HU9802132D0 (en) | Biphenyl-sulfonyl-cyanamides, process for producing them and their medical use | |
ZA978639B (en) | Use of 1-hydroxy-2-pyridones for the treatment of skin infections. | |
DE69734464D1 (de) | Verfahren zur expression und herstellung von rekombinantem, menschlichem beta-cis-interferon | |
EP0742019A4 (en) | GLASS MATERIAL, REPLACEMENT MATERIAL FOR LIVING TISSUE AND TOOTH REINFORCING MATERIAL | |
AU9764698A (en) | A fusion protein of hegf and human angiogenin, and process for preparing the same | |
AU3241895A (en) | Apoptosis related protein bcl-y, and methods of use thereof | |
AU3140697A (en) | The spindly gene, methods of identification and use | |
GB9916729D0 (en) | Fuller for the treatment of leather,pelts and the like | |
DE69535337D1 (de) | Transkriptionsfaktor e2f-5 | |
HUP0000785A3 (en) | Ointment for the treatment of burns and other skin diseases | |
AU3118095A (en) | Dna sequences coding for the human proteins tx and ty related to the interleukin-1beta converting enzyme | |
AU4037299A (en) | Genetically-modified fibroblasts and the use thereof | |
WO1998024482A3 (de) | Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung | |
AU5484598A (en) | Processed polypeptides with il-16 activity, processes for their production and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |